GlassScriptPhysician profile
Shangbo Guan
NPI 1811965957
$3,365.51
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.49 · 2021: $471 · 2022: $985 · 2023: $1,361 · 2024: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $479.19 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $438.02 | 2021-2024 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $246.36 | 2023 | |
| Emd Serono, INC. | $237.36 | 2021-2024 | Mavenclad |
| Gilead Sciences, INC. | $177.53 | 2019-2021 | |
| Abbott Laboratories | $142.03 | 2022 | |
| Lilly USA, LLC | $139.86 | 2022-2024 | Mounjaro |
| Lundbeck LLC | $134.15 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $132.50 | 2023 | Tarpeyo |
| Neurocrine Biosciences, INC. | $131.68 | 2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $130.68 | 2022 | |
| Jazz Pharmaceuticals INC. | $130.00 | 2021 | |
| Medtronic, INC. | $127.34 | 2023 | Intellis Adaptivestim |
| Dexcom, INC. | $120.49 | 2023 | Dexcom G7 Gss (161) |
| Amgen INC. | $119.87 | 2023 | Evenity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $119.08 | 2024 | |
| Harmony Biosciences LLC | $116.93 | 2022 | |
| Impel Pharmaceuticals INC. | $114.92 | 2022 | |
| Novo Nordisk INC | $110.51 | 2023 | |
| Idorsia Pharmaceuticals US INC | $17.01 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shangbo Guan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.